Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer

Breast Cancer Research and Treatment
X ZhuH Yang

Abstract

Paraffin sections from 239 cases of surgical resected mammary gland carcinomas were assessed to determine the role of BRCA1 gene methylation in sporadic triple-negative breast cancer and to evaluate the relationship between BRCA1 gene methylation and clinicopathologic features of triple-negative breast cancer in the National Cancer Center, China. Diagnostic tissues collected from patients received mastectomy in the National Cancer Center from January 1, 1999 to December 31, 2008 were reviewed. Tissue microarrays were constructed using 239 triple-negative breast cancer cases and stained with estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, cytokeratin 5/6, and epidermal growth factor receptor. Methylation status of the BRCA1 promoter was measured by methylation-specific PCR and analyzed against clinicopathologic characteristics, subtypes, and prognosis using standard statistical methods. Among the 239 triple-negative breast cancer cases, 137 (57.3 %) showed methylation of the BRCA1. According to the immunohistochemistry results, triple-negative breast cancer cases were classified into basal-like breast cancer (60.7 %) and non-basal-like breast cancer (39.3 %). The frequency of BRCA1 methylation...Continue Reading

References

Apr 6, 2000·Journal of the National Cancer Institute·M EstellerJ G Herman
Aug 30, 2000·Nature·C M PerouD Botstein
Jun 4, 2002·Nature Reviews. Genetics·Peter A Jones, Stephen B Baylin
Oct 18, 2002·Lancet·Richard D KennedyD Paul Harkin
Oct 2, 2003·Journal of the National Cancer Institute·William D FoulkesLars A Akslen
Aug 26, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Torsten O NielsenCharles M Perou
Nov 16, 2004·Genes, Chromosomes & Cancer·José PalaciosJavier Benítez
Jun 16, 2005·Current Opinion in Pharmacology·Nicholas TurnerAlan Ashworth
Aug 20, 2005·Nature Reviews. Cancer·William G Kaelin
Dec 13, 2005·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Chad A LivasyCharles M Perou
Feb 14, 2006·Cancer Cell·Andrea L RichardsonShridar Ganesan
Mar 25, 2006·Journal of Clinical Pathology·S BanerjeeI E Smith
Jun 4, 2008·Breast Cancer Research and Treatment·Xinran XuJia Chen
Jun 26, 2009·The New England Journal of Medicine·Peter C FongJohann S de Bono
Jul 1, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mieke KriegeJan G M Klijn
Nov 12, 2010·The New England Journal of Medicine·William D FoulkesJorge S Reis-Filho
Nov 26, 2010·Genes, Chromosomes & Cancer·Simon A JoossePetra M Nederlof
May 17, 2011·European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)·Alok Kumar SinghHausila Prasad Pandey
May 20, 2011·Epigenetics : Official Journal of the DNA Methylation Society·Olafur Andri StefanssonJorunn Erla Eyfjord
May 12, 2012·Cancer Discovery·Nicolai J BirkbakAndrea L Richardson
Jul 24, 2012·Virchows Archiv : an International Journal of Pathology·Amanjit BalGurpreet Singh
Feb 15, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y XuY Xie
Sep 13, 2013·Breast Cancer Research and Treatment·T IgnatovJ Bischoff
Nov 22, 2013·Breast Cancer Research and Treatment·Liang WuCheng Lu
Jan 9, 2014·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal

❮ Previous
Next ❯

Citations

Dec 23, 2015·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Jianfei Qi, Ze'ev A Ronai
Sep 28, 2018·International Journal of Cancer. Journal International Du Cancer·Catia MioFabio Puglisi
Mar 15, 2019·BMC Cancer·Bernardo P de AlmeidaPedro Castelo-Branco
Jul 13, 2018·Breast Cancer Research : BCR·Chuying WangXin-Hai Pei
Dec 22, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Douglass W TuckerDaniela M Dinulescu
Jul 26, 2019·The Breast : Official Journal of the European Society of Mastology·Shani Paluch-Shimon, Ella Evron
Oct 5, 2019·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Yehuda G AssarafM Helena Vasconcelos
Jan 23, 2021·Breast Cancer Research : BCR·Feng BaiXin-Hai Pei
Jan 26, 2021·Nanobiomedicine·Jananee Padayachee, Moganavelli Singh
Feb 20, 2021·Journal of Cancer Research and Clinical Oncology·Mangala Hegde, Manjunath B Joshi
Feb 12, 2017·Pharmacology & Therapeutics·Subhankar Biswas, C Mallikarjuna Rao
May 21, 2021·Biochimica Et Biophysica Acta. Reviews on Cancer·Talia GuardiaAikaterini Kontrogianni-Konstantopoulos

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.